Clinical Trial Update: Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase I trial update of Tolododekin Alfa (ANK-101) in advanced solid tumors. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Tolododekin Alfa (ANK-101)

Snippet

Sponsor: Ankyra Therapeutics, Inc | Conditions: Advanced Solid Tumor, Cutaneous Tumor | Phase 1 | Status: RECRUITING